PBJ ETF's small/mid-cap exposure, high expense ratio, and challenges from inflation and GLP-1 adoption make it a 'Sell'. Find ...

The proposal is expected to face strong pushback once again from drug manufacturers (read: A Look at Pharma ETFs After Strong Q1 Earnings). This policy has immediate implications for the ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

A federal court has struck down a major chunk of the president’s tariff agenda. - Investors were initially bullish after the ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. The ...

Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

The U.S. Department of Health and Human Services said on Tuesday it would set drug prices pegged to the lowest level paid by ...

These exchange-traded funds won't even need constant monitoring. In fact, you'd be better served in the long run by not ...

Trump’s push to tie Medicaid drug prices to lower international benchmarks could erase $1 trillion in revenues over 10 years. Amid the trends, pharma-targeted ETFs are being watched under a more ...

President Donald Trump announced plans to sign an executive order aimed at significantly reducing U.S. prescription drug prices by 30% to 80%. The initiative, known as the "most favored nation" policy ...